ANIX News and Press, Anixa Biosciences Inc. From 04/12/21

Piper Sandler paints an upbeat outlook for the synthetic biology (SynBio) space as the firm initiates coverage on Codexis (CDXS) and Twist Biosciences (TWST).Twist Bioscience and Codexis in focus as Piper Sandler sizes up synthetic biologyThe analyst Steven Mah predict the global market for s...

Anixa Biosciences (ANIX) and OntoChem will advance their COVID-19 antiviral candidates to the preclinical stage following successful proof-of-concept animal model study results.In the studies, the antivirals were shown to have no noticeable adverse effects, and weight impact and animal behavi...

Anixa Biosciences and OntoChem Enter Next Stage of Development for Covid-19 Therapeutic PR Newswire SAN JOSE, Calif. , April 5, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of can...

Gainers: Dolphin Entertainment (DLPN) +163%.Benitec Biopharma (BNTC) +88%.Liquid Media (YVR) +51%.Takung Art (TKAT) +35%.Evolve Transition Infrastructure (SNMP) +27%.Genius Brands International (GNUS) +17%.The ONE Group Hospitality (STKS) +17%.Glory Star New Media (GSMG) +16%.Funko ...

Gainers: Benitec Biopharma (BNTC) +71%, Hoth Therapeutics (HOTH) +26%, Aerpio Pharmaceuticals (ARPO) +12%, Soliton (SOLY) +11%, China Jo-Jo Drugstores (CJJD) +9%.Losers: Frequency Therapeutics (FREQ) -75%, Windtree Therapeutics (WINT) ...

Anixa Biosciences (ANIX) slumps 23.9% in premarket trade after underwriters agreed to increase its earlier announced offering and purchase on a firm commitment basis 4.29M shares at $5.25/share.Underwriters granted 30-day option to purchase up to an additional 642,857 shares.Gross p...

Frequency Therapeutics (FREQ) -71% after releases new data. from two FX-322 clinical studies; plans to advance single-dose regimen.Anixa Biosciences (ANIX) -23% after raises previously announced bought deal offering of common stock to $22.5M.Windtree Therapeutics (WIN...

Anixa Biosciences Increases Previously Announced Bought Deal Offering of Common Stock to $22.5 Million PR Newswire SAN JOSE, Calif. , March 22, 2021 /PRNewswire/ -- Anixa Biosciences, Inc.  (NASDAQ: ANIX) ("Anixa" or the "Company"), a biotechnology comp...

Anixa Biosciences (ANIX) announces a $10M bought deal offering of common stock through the issue of 1,904,762 shares priced at $5.25 per share.Underwriters' overallotment option is additional 285,714 shares.The company intends to use the net proceeds for general corporate purposes, inclu...

Anixa Biosciences Announces $10 Million Bought Deal Offering of Common Stock PR Newswire SAN JOSE, Calif. , March 22, 2021 /PRNewswire/ -- Anixa Biosciences, Inc.  (NASDAQ: ANIX) ("Anixa" or the "Company"), a biotechnology company focused on the treatment an...